High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a
| Autor: | Sylvia Bellucci, Bruno Cassinat, Kamel Ghomari, Pierre Fenaux, Sylvie Chevret, Jean-Jacques Kiladjian, Christine Chomienne, Philippe Rousselot, Marie-José Grange, Lina Abdelkader-Aljassem, William Vainchenker, Nathalie Parquet, Jean-Luc Dutel, Jean-François Bernard, Murielle Roussel, Gerald Massonnet, M L Menot, Nathalie Cambier, Pascal Turlure, Yasmina Chait, Jean-Didier Rain |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Genetic Markers Male medicine.medical_specialty Time Factors Immunology Clone (cell biology) Phases of clinical research Interferon alpha-2 Biochemistry Gastroenterology law.invention Polyethylene Glycols Polycythemia vera law hemic and lymphatic diseases Internal medicine Proto-Oncogene Proteins PEG ratio medicine Humans Point Mutation Allele Polycythemia Vera Polymerase chain reaction Aged Janus kinase 2 biology business.industry Interferon-alpha Cell Biology Hematology Janus Kinase 2 Middle Aged Protein-Tyrosine Kinases medicine.disease Minimal residual disease Recombinant Proteins biology.protein Female business |
| Zdroj: | Blood. 108(6) |
| ISSN: | 0006-4971 |
| Popis: | V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-alpha-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) of 27 treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P < .001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wild-type allele was observed during treatment. The results seem to confirm the hypothesis that IFN-alpha preferentially targets the malignant clone in PV and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. This trial was registered at www.clinicaltrials.gov as #NCT00241241. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|